UK biopharma Amryt has signed a distribution agreement with RCC Pharma for Lojuxta in Switzerland.
Lojuxta is a treatment for Homozygous Familial Hypercholesterolemia (HoFH), a rare, life-limiting disease, which impairs the body’s ability to remove LDL cholesterol from the blood.
Starting before birth, the disease progresses rapidly, and typically results in extremely high blood LDL cholesterol levels, which leads to aggressive and premature narrowing and blocking of blood vessels.
Left untreated, heart attack or sudden death may occur in childhood or early adulthood.
The Company currently estimates that there are approximately 15 patients with HoFH in Switzerland.
It has received requests from clinicians for access to Lojuxta for Swiss patients and this agreement will now enable Amryt to respond more effectively to such requests.
The new agreement follows a distribution agreement, announced on 13 November, which covers Amryt’s products for the Kingdom of Saudi Arabia.
Amryt acquired exclusive marketing rights for Lojuxta in the European Economic Area, Switzerland, Middle East, North Africa, Turkey and Israel in December 2016.
“This new distribution agreement with RCC marks another key step as we expand our footprint for Lojuxta across Europe, the Middle East, and North Africa,” said Dr Joe Wiley, Amryt CEO.
“We continue to work on further partnerships across our licensed territories for Lojuxta, and look forward to announcing further developments.”